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Abstract
Background: Chronic myeloid leukaemia (CML) is characterized by the expression of the BCR/ABL1 fusion gene, a
constitutively activated tyrosine kinase that commonly results from the formation of the Philadelphia (Ph)
chromosome after a t(9;22)(q34;q11) or variant rearrangement. The duplication of the Ph chromosome is a
recurring abnormality acquired during disease progression, whereas intrachromosomal amplification of BCR/ABL1 is
a rare phenomenon and has been associated with imatinib therapy resistance. Archival bone marrow chromosome
suspensions from 19 CML patients known to carry more than 1 copy of BCR/ABL1 and 10 CML cell lines were
analyzed by fluorescent in situ hybridization with a panel of probes from 9q34.1-qter to investigate whether they
carried two identical copies of the Ph chromosome or, instead, one or both Ph contained cryptic imbalances of
some regions.
Results: A duplication of the entire Ph chromosome with no further events involving the derivative 22 was found
in 12 patients. In contrast, a sideline with either 1 or 2 isochromosomes of the Ph chromosome was identified in
6 patients but none of the cell lines. In one of the patients a translocation between the distal end of one arm of
the isoderivative chromosome 22 and a third chromosome was revealed. 2 patients were found to carry marker
structures harbouring high copy number gains of BCR/ABL1 fusion along with a variable part of 9q34 region
downstream of ABL1 breakpoint, similarly to the markers present in the imatinib resistant cell line K562. We
identified the following regions of amplification: 9q34.1 ® q34.2 and 9q34.1 ® qter, with a common minimum
amplified region of 682 Kb. One of the patients had 5 BCR/ABL1 positive clones with variable level of 9q34
amplifications on a variety of structures, from an isoderivative 22 to tandem duplications.
Conclusions: These data confirm that the intrachromosomal genomic amplification of BCR/ABL1 that occurs in
some CML patients during disease progression also involves amplification of 9q34 gene-rich sequences
downstream of ABL1 breakpoint. The variety of rearrangements identified in this relatively small cohort
demonstrates that the Ph chromosome is not a stable structure but prone to further rearrangements during
disease progression.
Background
Chronic myeloid leukaemia (CML) is a malignant pluri-
potent haematopoietic stem cell disease characterized by
the expression of the BCR/ABL1 fusion gene, a constitu-
tively activated tyrosine kinase which commonly results
from the formation of the Philadelphia chromosome (Ph)
after a t(9;22)(q34;q11) or related variant rearrangement
[1]. Amplification of BCR/ABL1, as well as mutations of
the fusion gene, has been shown to be associated with
clinical resistance to imatinib therapy [2,3]. The blast
phase of CML is characterized by acquisition of new
cytogenetic abnormalities in 80% of the patients, the
most common being trisomy 8, duplication of the Ph
chromosome and isochromosome 17 [4]. The additional
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Ph chromosome houses a second copy of the BCR/ABL1
fusion resulting in genomic amplification of the chimeric
gene. In addition, extra copies of the fusion gene have
also been described housed by isochromosomes derived
from the Ph chromosome or marker structures contain-
ing tandem duplications of BCR/ABL1 fusion [5-8].
Moreover, a study using bacterial artificial chromosome
(BAC) array comparative genomic hybridization on CML
cell lines and patients [9] revealed unexpected gains of
the 9q34 region affecting BCR/ABL1 fusion and part of
the sequences telomeric to the fusion gene, which could
not be explained as due to a simple duplication of the Ph
chromosome.
In the present study, archival fixed bone marrow chro-
mosome suspensions from 19 CML patients and
10 CML cell lines known to carry more than 1 copy of
BCR/ABL1 fusion were analyzed by fluorescent in situ
hybridization (FISH) in order to investigate whether
CML patients with a double Ph have two exact copies
of the Ph chromosome or there are instead cryptic chro-
mosomal rearrangements involving BCR/ABL1 fusion
gene amplification as found in cell lines [9]. Using a
panel of BAC probes selected from the long arm of
chromosome 9, we screened for and mapped any rear-
rangements of the Ph chromosome involving gains of
the fusion gene. Apart from the duplication of the entire
Ph chromosome, we identified in six patients the pre-
sence of one or two isoderivative chromosome 22 [ider
(22)t(9;22)]. In two patients we detected marker struc-
tures harbouring high copy number gains of BCR/ABL1
fusion along with a variable part of the 9q34.12-qter
region downstream of ABL1 breakpoint, similarly to the
marker structures present in the imatinib resistant cell
line K562. One of the patients showed five BCR/ABL1
positive clones with variable level of 9q34.12-qter ampli-
fications on a variety of structures, from an ider(22)t
(9;22) to tandem duplications.
Results
The cytogenetic characteristics of the patients are pre-
sented in Table 1, while a schematic representation of
the 9q34 region indicating the relative position of the
BAC probes used for this study, as well as the relevant
genes, is shown in Figure 1. Initial FISH analysis with
the probes RP11-83J21 (band 9q34.12) and RP11-
323H21 (band 9q34.13) on metaphase cells identified
diverse cell populations based on the presence or
absence of a typical Ph chromosome: cells without a t
(9;22)(q34;q11); with one or two copies of the Ph chro-
mosome; with one or two isoderivative chromosome 22;
and with marker chromosomes derived from the Ph (see
Table 2). FISH confirmed the presence of two classical
Ph chromosomes in a subset of cells of all patients but
three (no. 11, 14, 18), one of which had indeed a variant
translocation involving the chromosomes 1, 9 and 22
with the BCR/ABL1 fusion located on two identical
markers der(1)t(1;22;9)(q21;q11;q34), mimicking a dupli-
cation of the Ph chromosome. The additional copy of
the Ph chromosome was the only rearrangement of the
Ph that was detected in twelve patients (no. 1-12). In
this group, patient no. 8 harboured a deletion of the
normal ABL1 gene on the non-translocated homologue
of chromosome 9 in Ph positive cells, while patients no.
9, 10 and 11 had variant translocations involving chro-
mosomes 17, 19 and 1, respectively.
In addition, a subset of cells from seven patients
tested positive for other gains of BCR/ABL1 fusion apart
from the presence of a second Ph chromosome. Two
types of chromosome abnormalities were found in these
cases: gains of the Ph chromosome taking the form of
an ider(22)t(9;22)(q34;q11) chromosome were detected
in six patients, while high copy number gains of only
part of the 9q34.1-qter region harboured by marker
structures derived from the Ph chromosome were found
in two patients (see Additional file 1). Remarkably, one
patient (no. 19) displayed five different BCR/ABL1
fusion positive cell clones with different degree of ampli-
fication, ranging from an ider(22)t(9;22)(q34;q11) to
markers with tandem duplications, and was therefore
included in both groups.
Metaphase FISH identifies cell populations with an
isoderivative chromosome 22, ider(22)t(9;22)(q34;q11), in
six patients
In six patients, a 5-7% of the analyzed metaphase cells
carried an isoderivative chromosome 22 replacing the
classical Ph chromosome (Figure 2). Five of these
patients (no. 13-15, 17, 19) had one ider(22)t(9;22)(q34;
q11) effectively representing two copies of a duplicated
Ph chromosome, but the sixth patient (no. 16) had two
ider(22)t(9;22)(q34;q11) resulting in the presence of four
copies of BCR/ABL1 fusion in the gene. All six patients
had a subclone of cells with only one Ph chromosome;
two patients had a Ph negative subclone of cells; and all
but one (no. 14) had a subclone with two Ph chromo-
somes. FISH with a commercial 9q sub-telomeric probe
confirmed the identity of the ider(22)t(9;22)(q34;q11)
hybridizing at both ends of the isochromosome in all
patients but one (no. 17), in whom the 9q sub-telomeric
probe unmasked a translocation between the ider(22)t
(9;22)(q34;q11) and a third chromosome, with one signal
from 9qter retained on the ider(22) and another one
moved to a marker chromosome. FISH mapping nar-
rowed the location of the translocation breakpoint to a
1.2 Mb region between RP11-413M3 (at 9q34.3) and the
9q sub-telomeric region. This patient was also found to
carry a cryptic deletion of the der(9)t(9;22)(q34;q11) that
only affected the 22q11 sequences telomeric to the
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ABL1/BCR fusion junction (3’ BCR), while the 9q34
sequences (5’ ABL1) were retained.
Although none of the other five patients with an iso-
derivative 22 had a deletion of the derivative 9, a cryptic
deletion of ABL1 sequences on the other homologue of
chromosome 9 [the one not involved in the t(9;22)(q34;
q11)] was present in 71% of the metaphases in one
patient (no. 13). Both cells with an additional Ph chro-
mosome and cells with an ider(22)t(9;22)(q34;q11) har-
boured this deletion. The remaining 29% metaphases
were also positive for the t(9;22)(q34;q11) but didn’t
carry the deletion.
Patient no. 19, with a complex variant translocation t
(9;22;17;11)(q34;q11.2;q11.2;q13), had five BCR/ABL1
fusion positive cell clones, four of them with gains of
the 9q34 region, one of which had an ider(22)t(9;22)
(q34;q11). In this patient, the cells with an isoderivative
Ph chromosome had three copies of the BCR/ABL1
fusion and 9q34.12-ter sequences: 1 copy on each arm
of the isoderivative Ph chromosome and a third copy on
an acrocentric chromosome marker.
Gains of BCR/ABL1 fusion and 9q34 region within marker
structures derived from the Ph chromosome
Marker structures containing multiple copies of BCR/
ABL1 fusion and part of the 9q34 region in the form of
tandem duplications were found in two patients (no.
18-19) (Figure 3). The size of the amplified region from
chromosome 9 was found to be very variable, with a
minimum size of the 9q34 amplicon of 682 Kb (no. 19)
and a maximum size of 7.23 Mb (no. 18).
Patient no. 18 was found to have an amplification of a
large region, from RP11-83J21 at 9q34.1 to RP11-413M3
at 9q34.3. FISH with probes from 9q34 gave a cluster of
multiple signals in 62 interphase cells (29%), while the
remaining 151 analyzed nuclei lacked the t(9;22)(q34;
q11) rearrangement, as evidenced by the two red, two
green signal pattern obtained with the use of a BCR/
ABL1 Dual Color, Dual Fusion Translocation Probe. All
BAC probes from the panel used in this study were
found to be amplified. However, hybridization with a 9q
sub-telomeric probe only gave 1 signal in the cells with
amplification of BCR/ABL1 fusion, indicating the
Table 1 Characteristics of the CML patient’s samples
ID Stage Karyotype BCR/ABL1 D-FISH (Interphase
FISH)
1 BC 46,XY,t(9;22)(q34;q11)[3]/47,idem,+der(22)t(9;22)(q34;q11)[7] NA
2 CP 46,XY,t(9;22)(q34;q11)[7]/47,idem,+der(22)t(9;22)(q34;q11)[7] NA
3 NA NA NA
4 NA NA NA
5 NA NA NA
6 NA NA NA
7 NA 46,XY,t(9;22)(q34;q11)/47,XY,idem,der(22)t(9,22)(q34;q11) NA
8 P- SCT 49,XY,+8,del(9)(q31?q34),t(9;22)(q34;q11),add(21)(q22),+add(21)(q22),+der(22)t(9;22)(q34;q11)[8]/46,XX[3] 2R2G[87]/1G3F[13]1
9 BC 46,XY,t(17;22)(q23;q11)t(9;22)(q34;q11)[8]/47,idem,+der(22)t(9;22)(q34;q11)[2]/48-50,idem,+Y,+8,+10,+der
(22)t(9;22)(q34;q11)[cp3]
NA
10 NA NA NA
11 R 47,XY,t(1;22;9)(q21;q11;q34),add(12)(q24),+der(22)t(1;22;9)t(22,?22)(q11;q11)[10] 1R2G1F[11]/1R2G2F[63]/2R2G
[26]2
12 BC 46,XY[1]/48-49,XY,t(9;22)(q34;q11),+der(22),+8,+8,+8,+8,t(20;21)(q12;q22)[19]inc 2R2G[210]/1R1G3F[17]
13 CP 46,XY,t(9;22)(q34;q11.2)[12]/47,idem,+der(22)t(9;22)[3] 2R2G[34]/1R1G2F[6]/1G2F[58]/
1G3F[6]1
14 P NA Metaphase FISH:2R2G[12]/
1R1G2F[5]/1R1 G3F[3]
15 AP 46,XY,t(9;22)(q34;q11)[1]/46,idem,der(19)t(?17;19)(q1?1;p13)[4]/47,idem,+der(22)t(9;22)(q34;q11)[5] 1R1G2F/1R1G3F
16 AP 46,XY,t(9;22)(q34;q11)[7]/55,idem,+8,+8,+14,+18,+18,+19,+21,+der(22)t(9;22)(q34;q11)[63]/46,XY[1] NA
17 BC-
BMT
?47-53,XY,t(9;22)(q34;q11),+der(22)t(9;22)(q34;q11),+1-7 mar[cp11] Metaphase FISH: 2R2G[3]/
2R1G1F[8]/2R1 G2F[9]3
18 R NA 2R2G[67]/1R1G5F[33]
19 BC 46,XY,t(9;22;17;11)(q34;q11.2;q11.2;q13)[2]/46,idem,add(5)(q?)[33]/47,idem,+der(22)t(9;22)(q34;q11)[?] NA
1 Deletion on the non-translocated homologue of chromosome 9.2 BCR/ABL1 fusion on der(1).3 Partial deletion of ABL1/BCR at der(9). Abbreviations: AP,
accelerated phase; BC, blast crisis; BC-BMT, blast crisis post sex mismatch bone marrow transplant; CP, chronic phase; NA, not available; P, presentation; P-SCT,
persistent post sex mismatch stem cell transplant; R, relapse.
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presence of a breakpoint between RP11-413M3 at
9q43.3 and the sub-telomeric region and thus delimiting
the length of the amplicon to 6.03-7.23 Mb. We were
only able to detect 43 metaphases, from which 42 were
negative for the t(9;22)(q34;q11) rearrangement while
only one was positive and contained the amplification.
The amplified signal was assigned to a marker
chromosome.
On the other hand, during disease progression several
subclones stemmed from the original Ph positive clone
present in patient no. 19 at diagnosis. Thus, different
secondary rearrangements of the Ph chromosome were
seen in different subclones showing increasing levels of
amplification: 3% of the metaphase cells had one Ph
chromosome; 44% had two Ph; 6% had one ider(22)t
(9;22)(q34;q11) with one copy of BCR/ABL1 fusion and
9q34.1-qter region on each arm, plus another copy of
the same region on a chromosome marker (mar1);
23.5% had one Ph, one marker (mar2) with tandem
repeats of 3’ABL1-RAPGEF1 region (1.09 Mb, from
RP11-83J21 to RP11-323H21) and one marker (mar3)
with duplication of 3’ABL1-NUP214 region (682 Kb,
from RP11-83J21 to RP11-643E14) (> 5 copies of
3’ABL1 and adjacent downstream sequences); and 23.5%
cells had one Ph and one marker (mar4) with high copy
number gains of 3’ABL1-NUP214 region 682 Kb, from
RP11-83J21 to RP11-643E14) (> 5 copies of 3’ABL1 and
adjacent downstream sequences). The latter chromo-
some marker contained such a high number of copies of
the amplified region that it appeared totally “painted”
when using any of the FISH BAC probes contained
within the amplified region.
Gains of BCR/ABL1 fusion and downstream region in
human CML cell lines
FISH screening of the cell lines for gains of BCR/ABL1
fusion and the region downstream of the ABL1 break-
point found the presence of at least two typical Ph chro-
mosomes in five out of the ten cell lines that were
analyzed: BV173, JK-1 and KCL-22 with two copies of
the Ph chromosome each, LAMA-84 with four copies
and EM-2 with either three, four or five copies. Addi-
tionally, the Ph negative BCR/ABL1 fusion positive cell
line CML-T1 with the fusion gene on a masked Ph had
three clones, all of them with a duplication of the
masked Ph resembling a classical duplication of the Ph
Figure 1 Schematic representation of the 9q34 region showing the position of the BAC probes. (A) Ideogram of chromosome 9
highlighting in red the 9q34 region that has been analyzed in this study. (B) Detail of the 9q34 region indicating the relative position of
relevant genes (left) and the BAC probes used in this study (right).
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Table 2 Summary of the FISH screening results with the probes RP11-83J21 (band 9q34.12) and RP11-323H21 (band
9q34.13)
ID Cell clones identified by metaphase FISH analysis Isoderivative Ph? High copy number gains in markers?
1 i. t(9;22)[1] No No
ii. t(9;22),+der(22)[19]
2 i. t(9;22)[18] No No
ii. t(9;22),+der(22)[2]
3 i. t(9;22),+der(22)[20] No No
4 i. t(9;22),+der(22)[20] No No
5 i. t(9;22),+der(22)[20] No No
6 i. t(9;22)[7] No No
ii. t(9;22),+der(22)[13]
7 i. t(9;22)[10] No No
ii. t(9;22),+der(22)[10]
8 i. No t(9;22)[12] No No
ii. t(9;22),del(9),+der(22)[8]1
9 i. t(9;22)[17] No No
ii. t(9;22),+der(22)[3]
10 i. No t(9;22)[6] No No
ii. t(9;22)[1]
iii. t(9;22),+der(22)[13]
11 i. t(1;22;9)[1] No No
ii. t(1;22;9),+der(22)t(1;22;9)[19]2
12 i. t(9;22),+der(22)[6]3 No No
13 i. t(9;22)[6] Yes No
ii. t(9;22),del(9) [12]1
iii. t(9;22),del(9),+der(22)[2]1
iv. t(9;22),del(9),ider(22)[1]1
14 i. No t(9;22)[10] Yes No
ii. t(9;22)[4]
iii. t(9;22),ider(22)[1]
15 i. t(9;22)[4] Yes No
ii. t(9;22),+der(22)[12]
iii. t(9;22),ider(22)[1]
16 i. t(9;22)[8] Yes No
ii. t(9;22),+der(22)[10]
iii. t(9;22),ider(22),+ider(22)[1]
17 i. No t(9;22)[7] Yes No
ii. t(9;22)[3]
iii. t(9;22),+der(22)[8]
iv. t(9;22),ider(22)[1]4
18 i. No t(9;22)[13] No Yes
ii. t(9;22),marker[1]
19 i. t(9;22)[1] Yes Yes
ii. t(9;22),+der(22)[15]
iii. t(9;22),ider(22),marker[2]
iv. t(9;22),marker[8]
v. t(9;22),marker,marker[8]
1Deletion on the non-translocated homologue of chromosome 9.2 BCR/ABL1 fusion on derivative 1.3 FISH analysis on interphase cells showed a ratio of normal
cells versus BCR/ABL1 positive cells (with an extra fusion signal) of 95% vs 5%.4 Further translocation of the isoderivative 22 with a marker chromosome.
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chromosome. The remaining cell lines displayed gains
that did not correspond to the presence of two identical
Ph chromosomes. KU812 and K562 displayed marker
chromosomes with high levels of amplification as seen
in two patients from this study, while MC3 and MEG-
01 harboured duplications within small chromosomes
resembling the standard Ph chromosome, a phenom-
enon that was not detected in any of the patients of this
study. None of the ten cell lines was found to have an
ider(22)t(9;22)(q34;q11). An overview of the cell lines
characteristics and the FISH results is presented in
Table 3.
The cell line KU812, described to have two Ph chro-
mosomes and two derivative 9 chromosomes, was found
to harbour a subclone with one Ph chromosome, two
derivatives 9 and a large chromosome marker with
homogeneously staining regions containing tandem
duplications of BCR/ABL1 fusion and part of down-
stream sequences (Figure 4). The chromosome marker
was detected in 20% of the cells and the 9q34 amplicon
was measured to be 1.09 Mb long, from RP11-83J21 to
RP11-323H21 (9q34.12-q34.13). In addition, the
sequences distal to RP11-323H21 (9q34.13-qter) were
also present at one end of the marker but only in one
copy.
On the other hand, the cell line K562 (Figure 5) lacks
a classical Ph but it does have two acrocentric markers
derived from the Ph chromosome harbouring the BCR/
ABL1 fusion. These two markers, described by Gribble
et al. [10] as der(22)t(9;13;22)(q34;q11;q11), contain high
Figure 2 Gains of the BCR/ABL1 fusion taking the form of an ider(22)t(9;22)(q34;q11). (A) A representative metaphase cell with co-
hybridization of FISH probes RP11-83J21 (3’ ABL1; signal in red) and 9qter (in green) as seen in patients no 14-15, showing a duplicated fusion
signal on the isoderivative 22 (block arrow) and a third fusion signal at 9q34 of the unrearranged homologue of chromosome 9. Top right,
close-up of the ider(22) DAPI banding. (B) A representative metaphase cell from patient no 13 with co-hybridization of FISH probes RP11-83J21
(in green) and RP11-323H21 (5’RAPGEF1; in red) showing a duplicated fusion signal on the isoderivative 22 (block arrow). A deletion of the
homologue of chromosome 9 not involved in the t(9;22) is detected by the hybridization of only the red signal from RP11-323H21. (C) A
representative metaphase cell from patient no 16 with co-hybridization of FISH probes RP11-83J21 (in green) and RP11-323H21 (in red) showing
the presence of four fusion signals on two isoderivative 22 chromosomes (block arrows) and a fifth fusion signal on the normal homologue of
chromosome 9. (D) A representative metaphase cell in patient no 17 with co-hybridization of FISH probes RP11-544A12 (NUP214; in green) and
9qter (in red), showing a normal 9 homologue and unmasking a cryptic translocation between the ider(22) (block arrow) and a marker
chromosome (dashed arrow).
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copy number gains of 22q11, BCR/ABL1 fusion, 9q34
and 13q31 sequences. The 9q34.12-q34.13 amplicon is
covered by three overlapping BAC clones, RP11-83J21,
RP11-143H20 and RP11-544A12, measuring 438 Kb.
Neither 9q nor 22q telomeres are present in these mar-
kers. In addition, K562 has a large chromosome der(9)t
(9;9) with the 9q34.12-qter region present in both arms,
an acrocentric chromosome der(9)t(9;17)(p?21;p?13)
containing a third copy of the 9q34.12-qter region, a
small marker chromosome derived from the short arm
of chromosome 9, and two apparently normal chromo-
somes 22.
Furthermore, duplications within apparently typical Ph
chromosomes were unmasked in two cell lines. MC3
had two Ph chromosomes with classical morphology,
but FISH with BAC probes revealed two clones, both
with different Ph chromosome markers containing cryp-
tic duplications. In the main clone, one of the two der
(22)t(9;22)(q34;q11) only carried a small fragment (682
Kb) from chromosome 9, from RP11-83J21 to RP11-
643E14 (9q34.12-q34.13), and did not carry neither 9q
nor 22q telomeres. The other derivative chromosome 22
retained all 3’ ABL1 ® 9qter sequences and also har-
boured a cryptic duplication of a 9q34.12-q34.13 frag-
ment from RP11-83J21 to RP11-544A12 (438 Kb long)
plus a duplication of the 9q telomere. In contrast,
another subset of cells had a Ph chromosome with a
typical morphology by G-banding carrying only a 438
Kb region from 9q34 (from RP11-83J21 to RP11-
544A12), which was also duplicated. In contrast, a dupli-
cation of the 9q telomere region (one in each arm) was
present on the other “Ph”, which retained all 3’ ABL1 ®
9qter sequences.
Finally, the cell line MEG-01 also had an apparently
typical Ph chromosome harbouring a duplication of
BCR/ABL1 fusion and 9q34 sequences. However, the
Figure 3 High copy number gains of BCR/ABL1 fusion and downstream region in two CML patients. (A) Representative interphase cells
from patient no. 18 with co-hybridization of FISH probes RP11-83J21 (signal in red) and RP11-323H21 (in green). Left, a cluster of fusion signals
was detected in 29% of cells. Right, 71% of cells showed only two signals corresponding to both normal homologues of chromosome 9. (B-F)
Representative metaphase cells from the cell clones found in patient no. 19, indicating the number of fusion signals and the percentage of cells
with that signal pattern. 3% of the metaphase cells had one Ph chromosome (B); 44% had two Ph (C); 6% had an isoderivative 22 Ph and a
fourth fusion signal on a marker chromosome (D); 23.5% had one Ph, one marker with tandem repeats of the 3’ABL1-RAPGEF1 region (1.09 Mb)
and one marker with duplication of the 3’ABL1-NUP214 region (682 Kb) (E); 23.5% cells had one Ph and one marker with high copy number
gains of the 3’ABL1-NUP214 region (682 Kb) (F).
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duplicated 9q34 fragment was larger, spanning 5.16 Mb
from RP11-83J21 to RP11-100C15, while the sequences
downstream of RP11-100C15 were missing in the atypi-
cal Ph but present on a chromosome identified as der(7)
t(7;22). MEG-01 was also found to have an acrocentric
chromosome, possibly a der(15)t(15;22)(?p11;q11), con-
taining BCR/ABL1 fusion and 9q34.12-qter sequences,
in addition to two der(9)t(9;22) chromosomes. It lacked
a normal chromosome 22 and a normal 9.
Discussion
Whereas intrachromosomal amplification of BCR/ABL1
is a rare phenomenon, the duplication of the Ph chro-
mosome resulting in two copies of the BCR/ABL1 fusion
gene is a common abnormality acquired during CML
disease progression, although it can be observed during
the chronic phase as well. Additional copies of the
fusion gene have been described in isochromosomes
derived from the Ph chromosome [5,11] and within
homogeneously stained regions in marker structures
acquired during disease progression, both in patients
treated with imatinib [6] or other therapies [7,12]. Using
BAC array comparative genome hybridization (CGH) on
CML patients and cell lines, Brazma et al. [9] identified
gains of 22q11.2 along with gains of BCR/ABL1 fusion
and only part of the 9q34.1-qter region, therefore not
corresponding to the presence of two typical Ph
chromosomes.
In our study, we used FISH with a range of BAC probes
from 9q34.1-qter on a collection of chromosome suspen-
sions from CML patients and human CML cell lines in
order to investigate whether the bone marrow cells with
an extra Ph chromosome carry indeed two identical
copies of the Ph or, instead, one or both Ph contain cryp-
tic imbalances of some regions. The dual colour FISH
assay that we designed and initially tested in all samples
contained the BAC clones RP11-83J21 and RP11-
323H21; the former targets the 3’ end of ABL1 gene
incorporating the whole of the coding region at 9q34.12
and was thus selected to detect the BCR/ABL1 fusion
Table 3 Metaphase FISH screening in human CML cell lines
Cell
line
Source Cell type Signal pattern with RP11-83J21(G) and
RP11-323H21(R) probes
Location of 9q
subtelomeric probe
Location of
22q
subtelomeric
probe
BV173 PB B cell precursor i. 2F: der(22)×2[20] i. der(22)×2 i. 22,der(9)
CML-
T11
PB T cell i. 3F: 9,der(22)×2 i. 9,der(9) NT
ii. 6F: 9×2,der(22)×4 ii. 9×2,der(9)×2
iii. 4F: der(22)×4 iii. der(9)×2
EM-2 BM Myeloid i. 3F: der(22)×3[1] i. der(22)×3 i. 22,der(9)×2
ii. 4F: der(22)×4[20] ii. der(22)×4
iii. 5F: der(22)×5[21] iii. der(22)×5
JK-1 BST Myeloid i. 3F: 9,der(22)×2[23] i. 9,der(22)×2 i. 22,der(9)
K562 PE Myeloid i. +5F: marker×2, der(9)t(9;17), der(9)t(9;9)
[20]
i. der(9)t(9;17), der(9)t(9;9) i. 22×2
KCL-22 PE Myeloid i. 3F: 9,der(22)×2[20] i. 9,der(22)×2 i. 22,der(9)
KU812 PB Myeloid early i. 2F: der(22)×2[15] i. der(22)×2 i. der(9)×2
basophilic ii. +5F: der(22), marker[9] ii. der(22), marker
LAMA-
84
PB Granulocytic, megakaryocytic and
erythroid
i. 4F: der(22)×4[20] i. der(22)×4 i. 22,der(9)×2
MC32 PB Myeloid, lymphoid and
megakaryocytoid
i. 2G: der(22)*,der(22)**
2F: 9,der(22)* [19]
i.
ii.
9,der(22)*
9,der(22)****
i.
ii.
22,der(9)
22,der(9)
ii. 2G: der(22)***
2F: 9,der(22)**** [3]
MEG-01 BM Megakaryoblastic i. 3F: der(22), der(15)t(15;22)[36] i. der(7)t(7;22), der(15)t
(15;22)
i. der(9)×2
1 CML-T1 is a Ph negative BCR/ABL1 positive cell line. The Ph chromosomes are indeed masked Ph chromosomes with an ins(22;9)(q11.2;q34.1q34.2). CML-T1 had
3 cell clones: one diploid and two tetraploid with/without a deletion of 9q34 on the “normal” 9.2 MC3 had two Ph chromosomes with apparently classical
morphology but FISH revealed the presence of two clones both with different Ph chromosome markers carrying cryptic duplications. Stars indicate the different
derivative chromosomes 22. Clone i., der(22)* retained all 3’ ABL1 ® 9qter sequences and carried a duplication of both 9q telomere and a 438 Kb fragment from
chromosome 9 (RP11-83J21 ® RP11-544A12); der(22)** only retained a 682 Kb fragment from 9 (RP11-83J21 ® RP11-643E14). Clone ii., der(22)*** only retained a
438 Kb region from 9 (RP11-83J21 ® RP11-544A12) which was duplicated; der(22) **** retained all 3’ ABL1 ® 9qter sequences and carried a duplication of 9q
telomere.
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gene, while the latter targets a region 730 Kb downstream
of the ABL1 gene and is present within the proximal
breakpoint cluster region as identified in Ph negative
BCR/ABL1 positive CML [13]. Each sample was initially
tested with this dual FISH probe set to screen for differ-
ences between the two Ph chromosomes with emphasis
on gains of ABL1 and the 9q34.12-q34.13 regions. Cases
with an unexpected FISH signal pattern differing from
the typical duplication of the Ph chromosome were
further characterized using a set of BAC FISH probes
from the 9q34.12-qter regions.
A simple duplication of the Ph chromosome with no
further events involving the derivative 22 was found in
twelve out of nineteen patients and six cell lines. In con-
trast, a sideline with either one or two isochromosomes
of the Ph chromosome was identified in six patients but
Figure 4 Gains of BCR/ABL1 fusion and a 1.09 Mb region from 9q34 in the cell line KU812. (A) Two representative metaphase cells
hybridized with a BCR/ABL1 dual colour, dual fusion FISH probe (D-FISH probe; Vysis) showing the primary clone (80% of cells) with an extra Ph
chromosome and a secondary clone (20% of cells) with one Ph and and a marker chromosome with tandem duplications of the BCR/ABL1
fusion (block arrow). (B) Ideograms showing the hybridization signal pattern of the BCR/ABL1 D-FISH probe on the primary (top) and secondary
(bottom) clones. There are no normal copies of neither chromosome 9 nor chromosome 22. (C) Representative metaphase cell from the
secondary clone with co-hybridization of RP11-40A7 (signal in red) and RP11-323H21 (5’ RAPGEF1; in green) showing one fusion signal on a Ph
chromosome and tandem duplications of the fusion signal on a marker chromosome (block arrow). Top right, ideogram showing the FISH signal
pattern obtained with these probes. Bottom, a close-up of the DAPI banding of the marker chromosome harbouring the tandem duplications.
(D) Close-up of a representative metaphase co-hybridized with RP11-544A12 (in green) and RP11-81P5 (in red) showing just one signal from the
latter on the marker chromosome (block arrow). An ideogram with the hybridization signal patterns of the two probes is shown on the right.
The distal breakpoint of the 9q34 amplicon falls between RP11-323H21 and RP11-81P5 and is estimated to measure approx. 1.09 Mb. Sequences
downstream of the distal breakpoint of the 9q34 amplicon also hybridized on the marker chromosome but were not amplified. (E) Close-up and
ideogram of the amplified marker with co-hybridization of 9q and 22q sub-telomeric probes (in red and green, respectively).
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none of the cell lines. The presence of multiple copies of
the isoderivative Ph chromosome is a rare rearrange-
ment that has been previously described [14,15]. In one
of our patients a translocation between the distal end of
one arm of the isoderivative chromosome 22 and a mar-
ker chromosome was revealed. It should be noted than
in our study the clone carrying the ider(22)t(9;22)(q34;
q11) represents only a small proportion of the BCR/
ABL1 fusion positive cells (around 5%) in contrast with
the cases previously reported, however the clinical sig-
nificance of the presence in such a small population of
cells cannot be defined. One out of the six patients with
ider(22)t(9;22)(q34;q11) and a seventh patient were
found to carry tandem duplications of the fusion gene
and further material from chromosome 9 within marker
chromosomes derived from the der(22)t(9;22). We
demonstrated the following regions of amplification:
9q34.1 ® q34.2 and 9q34.1 ® qter, with a common
minimum amplified region of 682 Kb. One of the two
patients had developed indeed two sidelines with two
different marker chromosomes harbouring 9q34 ampli-
cons, apart from the sideline with an isoderivative chro-
mosome 22. Similar amplifications were identified in the
imatinib resistant cell line K562, as well as in KU812.
Gadzicki et al. [16] showed that genomic BCR/ABL1
fusion amplification resulted in an increase level of
BCR/ABL1 transcript. However, our study was made
with archival stored chromosome suspensions and
neither DNA nor RNA material from these samples was
available to investigate the expression levels. Morel et al.
[17] also reported the amplification of BCR/ABL1 in
multiple double minutes (3-30) in a CML patient with
imatinib resistance, but none of the patients from the
present study contained such structures. Instead, the
intrachromosomal amplification of BCR/ABL1 fusion
seen in chromosome markers in our two patients is very
similar to amplification of the fusion gene in each of the
two BCR/ABL1 fusion positive markers of the cell line
K562, although the distal breakpoints of the amplicon
are different. We detected the presence of a subclonal
cell population in two cell lines, KU812 and MC3. Even
though they may be an in vitro artifact resulting from
repeated passaging, it is interesting that in KU812 the
acrocentric chromosome marker that harbours tandem
duplications of BCR/ABL1 fusion and a 1 Mb long 9q34
amplicon is similar to the chromosome markers that
some CML patients acquire in vivo, suggesting the pos-
sibility that this subclone had already been present in
the original sample when the cell line was established
and had expanded under in vitro cell culture conditions
thanks to a proliferative advantage.
Conclusions
In summary, 58% of the patients and 50% of the cell
lines were found to harbour two identical Ph chromo-
somes, while the remaining cases had isoderivative chro-
mosomes 22 or gains of BCR/ABL1 fusion gene
accompanied by 9q34 material harboured by marker
chromosomes. Taken together, these data confirm that
the genomic amplification of BCR/ABL1 fusion that
occurs in some CML patients during disease progression
also involves amplification of 9q34 gene-rich sequences
Figure 5 Gains of BCR/ABL1 fusion and a 438 Kb region from 9q34 in the cell line K562. (A) A representative metaphase cell and
interphase cell with co-hybridization of FISH probes RP11-83J21 (3’ ABL1; signal in red) and RP11-544A12 (NUP214; in green) showing two
acrocentric markers der(22)t(9;13;22)(q34;q11;q11) (indicated by block arrows) with multiple fusion signals, plus two fusion on a der(9)t(9;9) and
one fusion signal on a der(9)t(9;17). (B) A representative metaphase cell and interphase cell with co-hybridization of FISH probes RP11-643E14 (in
red) and RP11-323H21 (5’ RAPGEF1; in green) showing just two fusion signals on der(9)t(9;9) and one on der(9)t(9;17), with no hybridization on
the markers with BCR/ABL1 amplification. The distal breakpoint of the amplicon falls between RP11-544A12 and RP11-643E14 and the amplified
region from 9q34 is estimated to be 438 Kb long. (C) Representative metaphase cell with co-hybridization of 9q and 22q sub-telomeric FISH
probes (in red and green, respectively) showing two signals from 22qter on two chromosomes 22 and three signals from 9qter on both arms of
der(9)t(9;9) and on der(9)t(9;17).
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downstream of ABL1 breakpoint. Moreover, the variety
of rearrangements and breakpoints identified in this
relatively small cohort of CML patients’ samples shows
that the Ph chromosome is not a stable structure but
prone to further rearrangements during disease
progression.
Methods
Patients
Archival fixed chromosome suspensions (stored at -20°
C) from the bone marrow of nineteen CML patients
with either more than 1 Ph detected by G-banding or
more than one copy of BCR/ABL1 fusion detected by
FISH were donated anonymously for further analysis by
the Hammersmith Hospital, the University College Hos-
pital and the Royal Free Hospital (London, UK); and St
Anna Hospital (Sofia, Bulgaria). The samples were ori-
ginally taken between the years 1998 and 2008 for the
detection of the t(9;22)(q34;q11). Eleven patients carried
a typical t(9;22)(q34;q11) and three patients carried var-
iant translocations. Neither the karyotype nor the FISH
results were available for the remaining five samples. In
addition, multiple copies of BCR/ABL1 fusion had been
detected by interphase FISH in one patient.
Cell lines
Ten human CML cell lines (BV173, CML-T1, EM-2, JK-
1, K562, KCL-22, KU812, LAMA-84, MC3 and MEG-
01) were obtained from the German Collection of
Microorganisms and Cell Cultures/Department of
Human and Animal Cell Cultures (DSMZ, Braunsch-
weig, Germany). Cells were cultured in RPMI 1640
medium (Invitrogen, Paisley, UK) supplemented with
10-20% (v/v) foetal bovine serum (Invitrogen, Paisley,
UK), 1% (v/v) L-glutamin (Invitrogen, Paisley, UK) and
1% (v/v) penicillin/streptomycin (Invitrogen, Paisley,
UK) at 37°C in 5% CO2. Cells were blocked at the meta-
phase stage by treatment with Colcemid (Invitrogen,
Paisley, UK) and chromosomes harvested by means of a
hypotonic treatment (0.075 M KCl) followed by fixation
with methanol-acetic acid (3:1).
Fluorescence in situ hybridization (FISH)
FISH studies were performed on interphase and meta-
phase cells using a panel of BAC probes from 9q34.1-
qter. BAC clones were selected according to the UCSC
genome browser (University of California Santa Cruz,
CA, USA), assembly NCBI36/hg18, and obtained from
the BACPAC Resources Center (Children’s Hospital
Oakland Research Institute, Oakland, CA, USA), the
Sanger Centre (Cambridge, UK) and Invitrogen (Paisley,
UK). After growth in LB medium (Sigma-Aldrich, Dor-
set, UK) with chloramphenicol, the DNA was extracted
with a QIAGEN Large-Construct Kit (Qiagen, West
Sussex, UK), directly labelled with either Spectrum
Orange or Spectrum Green dUTPs (Vysis Inc., Downers
Grove, IL, USA) with a Nick Translation Kit (Vysis Inc.,
Downers Grove, IL, USA), precipitated with ethanol and
resuspended in hybridization buffer composed of 50%
formamide, 10% dextran sulphate (Sigma-Aldrich, Dor-
set, UK), 0.1% Tween 20 (Sigma-Aldrich, Dorset, UK)
and 10 mM Tris in 2 × SSC. Each clone was first tested
on normal human metaphase cells in order to verify the
mapping location. All tests were carried out as dual
colour, dual locus FISH experiments. Commercial sub-
telomeric FISH probes from 9q and 22q (Stretton Scien-
tific Ltd, Stretton, UK) were used according to the
manufacturer’s instructions to identify the location of
the telomeres, while FISH with the commercially avail-
able LSI BCR/ABL1 Dual Color, Dual Fusion Transloca-
tion Probe (Vysis Inc., Downers Grove, IL, USA) was
performed on the cell lines following the manufacturer’s
protocol.
Fresh slides were made from chromosome suspensions
and aged overnight at room temperature. Briefly, the
slides were treated with RNase A (100 μg/ml in 2 × SSC;
1 hour, 37°C), digested with pepsin (0.025% in 0.01 N
HCl; 8 minutes, 37°C), dehydrated in a graded ethanol
series (70%-90%-100%; 2 minutes each), and denatured in
70% formamide/2 × SSC (2 minutes; 72°C) followed by
dehydration in ice-cold ethanol series. Denatured probes
(73°C, 5 minutes) were applied to the slides. After over-
night hybridization at 37°C, the slides were washed in
0.4× SSC/0.3% IGEPAL (73°C, 5 minutes) and two times
in 2 × SSC/0.1% IGEPAL (37°C, 5 minutes). The cells
were counterstained with 4,6-diamidino-2-phenylindole
(Vysis Inc., Downers Grove, IL, USA) in Vectashield
mounting medium (Vector Laboratories, Burlingame,
CA, USA) for chromosome visualization. FISH analysis
was carried out using an automated epifluorescence
microscope (BX61, Olympus UK Ltd, Essex, UK)
equipped with a CCD camera (ORCAII-ER, Hamma-
matsu Photonics UK Ltd., Hertfordshire, UK). Digital
images were captured using SmartCapture 3 software
(Digital Scientific Ltd., Cambridge, UK).
Additional material
Additional file 1: FISH mapping carried out on the CML patient
showing for each case the number of signals obtained with each
probe and their location.
Acknowledgements
We thank Alistair Reid, Helen Mazzullo and D. Toncheva for kindly providing
some of the samples for this study. AV was supported by a grant from the
Anthony Nolan Trust. This work was supported by the Leukaemia Research
Fund (No. 05098, Jean Coubrough Charitable Trust Project).
Virgili and Nacheva Molecular Cytogenetics 2010, 3:15
http://www.molecularcytogenetics.org/content/3/1/15
Page 11 of 12
Authors’ contributions
AV carried the FISH studies and drafted the manuscript. EPN conceived and
designed the study, and helped to draft the manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 June 2010 Accepted: 1 September 2010
Published: 1 September 2010
References
1. Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease
evolution in human cancer. Nature reviews 2007, 7:441-453.
2. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN,
Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-
ABL gene mutation or amplification. Science (New York, NY) 2001,
293:876-880.
3. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T,
Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ,
Hehlmann R: Molecular and chromosomal mechanisms of resistance to
imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
4. Quintas-Cardama A, Cortes J: Molecular biology of bcr-abl1-positive
chronic myeloid leukemia. Blood 2009, 113:1619-1630.
5. Szych CM, Liesveld JL, Iqbal MA, Li L, Siebert S, Asmus C, O’Malley J, Lee A,
Wang N: Isodicentric Philadelphia chromosomes in imatinib mesylate
(Gleevec)-resistant patients. Cancer genetics and cytogenetics 2007,
174:132-137.
6. Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J:
BCR/ABL amplification in chronic myelocytic leukemia blast crisis
following imatinib mesylate administration. Cancer genetics and
cytogenetics 2002, 139:30-33.
7. Gargallo PM, Cuello MT, Aranguren PN, Larripa IB: Amplification of the
BCR/ABL fusion gene clustered on a masked Philadelphia chromosome
in a patient with myeloblastic crisis of chronic myelocytic leukemia.
Cancer genetics and cytogenetics 2003, 143:140-144.
8. Phan CL, Megat Baharuddin PJ, Chin LP, Zakaria Z, Yegappan S, Sathar J,
Tan SM, Purushothaman V, Chang KM: Amplification of BCR-ABL and t
(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Cancer genetics and cytogenetics 2008, 180:60-64.
9. Brazma D, Grace C, Howard J, Melo JV, Holyoke T, Apperley JF, Nacheva EP:
Genomic profile of chronic myelogenous leukemia: Imbalances
associated with disease progression. Genes, chromosomes & cancer 2007,
46:1039-1050.
10. Gribble SM, Roberts I, Grace C, Andrews KM, Green AR, Nacheva EP:
Cytogenetics of the chronic myeloid leukemia-derived cell line K562:
karyotype clarification by multicolor fluorescence in situ hybridization,
comparative genomic hybridization, and locus-specific fluorescence in
situ hybridization. Cancer genetics and cytogenetics 2000, 118:1-8.
11. Pernice F, Squadrito G, Saitta A, Mazza G, Musolino C: Isodicentric
Philadelphia chromosome in accelerated phase of chronic myeloid
leukemia. Cancer genetics and cytogenetics 1993, 66:113-116.
12. Metzke-Heidemann S, Harder L, Gesk S, Schoch R, Jenisch S, Grote W,
Siebert R, Schlegelberger B: Integration of amplified BCR/ABL fusion
genes into the short arm of chromosome 17 as a novel mechanism of
disease progression in chronic myeloid leukemia. Genes, chromosomes &
cancer 2001, 31:10-14.
13. Virgili A, Brazma D, Reid AG, Howard-Reeves J, Valganon M, Chanalaris A,
De Melo VA, Marin D, Apperley JF, Grace C, Nacheva EP: FISH mapping of
Philadelphia negative BCR/ABL1 positive CML. Molecular Cytogenetics
2008, 1:14.
14. Li Ming Chua C, Tan YY, Chua SP, Ma HB, Koay E, Li Min Poon M, Liu TC,
Gole L: Multiple copies of a rare rearrangement of Philadelphia
chromosome in a chronic myeloid leukemia patient: a case report.
Cancer genetics and cytogenetics 2010, 199:66-68.
15. Sirulink A, Silver RT, Najfeld V: Marked ploidy and BCR-ABL gene
amplification in vivo in a patient treated with STI571. Leukemia 2001,
15:1795-1797.
16. Gadzicki D, von Neuhoff N, Steinemann D, Just M, Busche G, Kreipe H,
Wilkens L, Schlegelberger B: BCR-ABL gene amplification and
overexpression in a patient with chronic myeloid leukemia treated with
imatinib. Cancer genetics and cytogenetics 2005, 159:164-167.
17. Morel F, Bris MJ, Herry A, Calvez GL, Marion V, Abgrall JF, Berthou C,
Braekeleer MD: Double minutes containing amplified bcr-abl fusion gene
in a case of chronic myeloid leukemia treated by imatinib. European
journal of haematology 2003, 70:235-239.
doi:10.1186/1755-8166-3-15
Cite this article as: Virgili and Nacheva: Genomic amplification of BCR/
ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a
FISH mapping study of CML patients and cell lines. Molecular
Cytogenetics 2010 3:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Virgili and Nacheva Molecular Cytogenetics 2010, 3:15
http://www.molecularcytogenetics.org/content/3/1/15
Page 12 of 12
